Pancreas

Novotech Publishes Analyst Report on Cystic Fibrosis Clinical Trial Landscape to Inform Biotech Research Planning 

Retrieved on: 
Jeudi, avril 11, 2024
Contract research organization, Mutation, Epithelium, Pancreas, Investment, SWOT, Cystic fibrosis, CFTR, USFDA, Growth, Therapy, Patient, Research report, Medicine, ROW, Life expectancy, Standard of care, Clinical trial, Quality of life, Longevity, Prevalence, Pharmaceutical industry

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) --  Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report entitled Cystic Fibrosis - Global Clinical Trial Landscape.

Key Points: 
  • BOSTON, April 10, 2024 (GLOBE NEWSWIRE) --  Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report entitled Cystic Fibrosis - Global Clinical Trial Landscape.
  • The report presents a data-backed review of the Cystic Fibrosis (CF) funding landscape, trial density and patient recruitment data across geographies, standard of care and emerging therapies, recent USFDA approvals, and regulatory trends.
  • Importantly it also includes an in-depth SWOT analysis, to guide biotech firms on strategic decision-making, and research opportunities, and challenges.
  • The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.

Molecular You Announces Breakthrough in Early Detection of Pancreatic Cancer

Retrieved on: 
Lundi, avril 22, 2024
Pancreatic cancer, Blood, Health, Female, Attention, Disease, Pancreas, Family, OMICS, Patient, Biopsy, Malignancy, Biomarker, Algorithm, Medical imaging

PORTLAND, Ore., April 22, 2024 /PRNewswire/ -- Molecular You , a leading health technology company specializing in personalized medicine, has achieved a significant milestone in the early detection of pancreatic cancer.

Key Points: 
  • PORTLAND, Ore., April 22, 2024 /PRNewswire/ -- Molecular You , a leading health technology company specializing in personalized medicine, has achieved a significant milestone in the early detection of pancreatic cancer.
  • Having established a multi-omic blood testing and analysis platform, designed to monitor patients longitudinally for the early detection and intervention of over 26 diseases, Molecular You has now determined a method for identifying stage 1 pancreatic cancer.
  • On her most recent Molecular You assessment, a series of blood based biomarkers were identified in ranges associated with pancreatic cancer.
  • The early detection by the Molecular You platform allows for life-saving surgical intervention, and establishes the multi-omic biomarkers and algorithms developed by Molecular You as a promising method for the detection of pancreatic cancer in the initial stages.

New Findings in JNCCN Illustrate Pathway for Screening High-Risk Individuals for Pancreatic Cancer in PRECEDE Study

Retrieved on: 
Mardi, avril 16, 2024
University, Clinical trial, NCCN, Pancreas, McGill University Health Centre, Risk, Pancreatic cancer, Breast, Prevalence, Cancer, National Comprehensive Cancer Network, Rosalind, Survival, Survival rate, Cyst, Doctor of Philosophy, Huntsman Cancer Institute, Research, Moores Cancer Center, Consortium, Disease, Incidence, Patient, Pancreatic Cancer Action Network, Diagnosis, Research institute, PGV, Dana–Farber Cancer Institute, Morávek, UC, McGill University, Pharmaceutical industry

PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer. Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%. When pancreatic neoplasms are detected early enough for treatment with surgical resection, the survival rate climbs to better than 80%, but unfortunately the vast majority of patients are diagnosed with advanced-stage disease. The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease. Of 1,759 participants sorted into the highest-risk cohort, nearly 80% completed baseline imaging through PRECEDE.

Key Points: 
  • Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%.
  • The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease.
  • "I look forward to further research... to improve access to pancreatic cancer screening for high-risk individuals."
  • "Longer follow-up time is needed to determine if familial pancreatic cancer signifies a higher risk for developing pancreatic cancer compared to pathogenic germline variant (PGV) status in a pancreatic cancer predisposition gene."

NUH LAUNCHES NEW DIGESTIVE CENTRE TO PUSH NEW FRONTIERS IN EARLY CANCER DETECTION AND CARE EXCELLENCE

Retrieved on: 
Mardi, avril 16, 2024
Radiation, Cade, Cancer, CAQ, Mouth, Pancreas, Tissue, AI, Colorectal cancer, Prognosis, Annual report, Stomach, Surgeon, Digestate, Artificial intelligence, Stomach cancer, Consultant, Hepatology, Radiology, National University Hospital, Computer, Incidence, Patient, Endoscopy, Diagnosis, Biomarker, Associate, Liver cancer, Division, Head, NUH, Medical imaging

SINGAPORE, April 16, 2024 /PRNewswire/ -- The National University Hospital (NUH) is embarking on a major initiative to establish the National University Centre for Digestive Health, slated for completion in the first half of 2025. With a vision to be the region's leading academic centre for digestive health, the Centre will pioneer research, innovations and clinical practices with an amplified focus to elevate the standards of early disease detection, precise diagnosis, treatment and prevention of digestive illnesses.

Key Points: 
  • Early gastrointestinal lesions, which are abnormal changes involving the tissues in the stomach area, may be indicative of cancer.
  • As such, early detection and diagnosis are crucial for better prognosis and lay a strong foundation for successful treatment and recovery.
  • The team is also developing novel biomarkers to improve the precision of early colorectal cancer detection, as well as new pancreas and liver cancer assays.
  • As we continue to expand our infrastructure and embrace technological advances, the Centre is poised to redefine digestive health for the future."

Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options

Retrieved on: 
Vendredi, avril 19, 2024
MOD, Hyperinsulinemia, MARD, First Nations, Human, Obesity, Cell, Indigenous peoples, Unique, Disease, Blood transfusion, Insulin, Diabetes, Risk, Patient, Fatty liver disease, Weight loss, Stroke, Research, Fetus, Metabolic disorder, Hope, Pregnancy, Eye disease, Life, Kidney disease, Type 2 diabetes, Pancreas, Paratriathlon, SIDD, Blood, Type, Type 2, Dietary supplement

You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?

Key Points: 
  • You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?
  • In Canada, diabetes affects approximately 10 per cent of the general population.

Locks and keys

  • Every cell in the body needs sugar as an energy source, but too much sugar can be toxic to cells.
  • This equilibrium needs to be tightly controlled and is regulated by a lock and key system.
  • Cells cover themselves with locks that respond perfectly to insulin keys to facilitate the entry of sugar into cells.
  • The body can encounter difficulties producing an adequate number of insulin keys, and/or the locks can become stubborn and unresponsive to insulin.

Severe insulin-deficient diabetes: We’re missing keys!

  • In the severe insulin-deficient diabetes (SIDD) subtype, the key factories — the beta cells — are on strike.
  • Why the beta cells go on strike remains largely unknown, but since there is an insulin deficiency, treatment often involves insulin injections.

Severe insulin-resistant diabetes: But it’s always locked!

  • In the severe insulin-resistant diabetes (SIRD) subtype, the locks are overstimulated and start ignoring the keys.
  • There are many treatment avenues for these patients but no consensus about the optimal approach; patients often require high doses of insulin.

Mild obesity-related diabetes: The locks are sticky!

  • Mild obesity-related (MOD) diabetes represents a nuanced aspect of Type 2 diabetes, often observed in individuals with higher body weight.
  • The locks are “sticky,” so it is challenging for the key to click in place and open the lock.

Mild age-related diabetes: I’m tired of controlling blood sugar!


Mild age-related diabetes (MARD) happens more often in older people and typically starts later in life. With time, the key factory is not as productive, and the locks become stubborn. People with MARD find it tricky to manage their blood sugar, but it usually doesn’t lead to severe complications. Among the different subtypes of diabetes, MARD is the most common.

Unique locks, varied keys

  • In Canada, unique cases of Type 2 diabetes were identified in Indigenous children from Northern Manitoba and Northwestern Ontario by Dr. Heather Dean and colleagues in the 1980s and 90s.
  • Read more:
    Indigenous community research partnerships can help address health inequities

    Childhood-onset Type 2 diabetes is on the rise across Canada, but disproportionately affects Indigenous youth.

  • Acknowledging this distinct subtype of Type 2 diabetes in First Nations communities has led to the implementation of a community-based health action plan aimed at addressing the unique challenges faced by Indigenous Peoples.

A mosaic of conditions

  • Type 2 diabetes is not uniform; it’s a mosaic of conditions, each with its own characteristics.
  • Since diabetes presents so uniquely in every patient, even categorizing into subtypes does not guarantee how the disease will evolve.


Lili Grieco-St-Pierre receives funding from Fonds de recherche du Québec - Santé (FRQS). Jennifer Bruin receives funding from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), JDRF, Diabetes Canada.

Good news: midlife health is about more than a waist measurement. Here’s why

Retrieved on: 
Vendredi, avril 19, 2024
Incidental, Eating, Death, Body composition, Health, Overweight, Diet, Conditional sentence, Longevity, Hormone, Motivation, Facial muscles, Exercise, Woman, Disease, Connective tissue, Vital signs, Energy, Risk, Genetics, Inflammation, Metabolism, Patient, DSM-IV codes, GP, Extrapyramidal system, Lung, Mental health, Abdomen, Menopause, Weight, Research, Cancer, Food, Parenting, Life, Insulin resistance, Body mass index, Skin, Heart, Pancreas, Lipid metabolism, Waist, Dicarboxylic acid, BMI, Liver, Movement, Parent, Dietary supplement

During the appointment they measure your waist.

Key Points: 
  • During the appointment they measure your waist.
  • GPs and health professionals commonly measure waist circumference as a vital sign for health.
  • Men are at greatly increased risk of health issues if their waist circumference is greater than 102 centimetres.
  • More than two-thirds of Australian adults have waist measurements that put them at an increased risk of disease.

How much is too much?

  • A ratio of 0.6 or more places a person at the highest risk of disease.
  • This can kick off a discussion about their risk of chronic diseases and how they might address this.
  • For women, hormone levels begin changing in mid-life and this also stimulates increased fat levels particularly around the abdomen.
  • Finally, your family history and genetics can make you predisposed to gaining more abdominal fat.

Why the waist?

  • Visceral fat surrounds and infiltrates major organs such as the liver, pancreas and intestines, releasing a variety of chemicals (hormones, inflammatory signals, and fatty acids).
  • These affect inflammation, lipid metabolism, cholesterol levels and insulin resistance, contributing to the development of chronic illnesses.
  • In addition to the direct effects of hormone changes, declining levels of oestrogen change brain function, mood and motivation.
  • These psychological alterations can result in reduced physical activity and increased eating – often of comfort foods high in sugar and fat.
  • And importantly, the waist circumference (and ratio to height) is just one measure of human health.

Muscle matters

  • On current evidence, it is equally or more important for health and longevity to have higher muscle mass and better cardiorespiratory (aerobic) fitness than waist circumference within the healthy range.
  • So, if a person does have an excessive waist circumference, but they are also sedentary and have less muscle mass and aerobic fitness, then the recommendation would be to focus on an appropriate exercise program.
  • Conversely, a person with low visceral fat levels is not necessarily fit and healthy and may have quite poor aerobic fitness, muscle mass, and strength.

Getting moving is important advice

  • Exercise can counter a lot of the negative behavioural and physiological changes that are occurring during midlife including for people going through menopause.
  • And regular exercise reduces the tendency to use food and drink to help manage what can be a quite difficult time in life.
  • Measuring your waist circumference and monitoring your weight remains important.


Rob Newton receives funding from National Health and Medical Research Council, the Medical Research Future Fund, Cancer Council Western Australia, Spinal Cord Injuries Australia and the World Cancer Research Fund. Rob Newton is a board member of The Healthy Male.

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Retrieved on: 
Jeudi, avril 18, 2024
Eurostat, Diagnosis, Civil service commission, Absorption, Lower respiratory tract infection, Exercise, Cell, Infection, DSM-IV codes, Inflammation, Patient, Committee, Cystic fibrosis, Knowledge, Digestion, Regulation, Bacteria, Food, EMA, IRIS, Anti-inflammatory, Mucus, CB2, European, COMP, Pancreas, Sponsor, Ivacaftor, European Commission, Safety, CFTR, Marketing, Medicine, Pharmaceutical industry

Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Key Points: 


Orphan designation: (6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid- Treatment of cystic fibrosis, 14/10/2016 Withdrawn

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Lundi, avril 1, 2024
Research, Glucose, Health, Congress, Obesity, Human, Drug discovery, Exercise, Glycated hemoglobin, DMR, ADAS, Partnership, Insulin, IDA, Patient, Weight loss, Michigan Medicine, Diabetes, Public expenditure, IDE, University, IPO, Tropism, Peptide, Transgene, Insulin resistance, Animal, NUB, Type 2 diabetes, Pancreas, Investigational New Drug, Therapy, Food, Marketing, FDA, Engineering, Annual general meeting, Pharmaceutical industry

BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today reported its fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • “In addition, we expect to complete enrollment of our pivotal Revitalize-1 study and are excited to report topline data in the fourth quarter of 2024.
  • The Company expects to complete enrollment in the first half of 2024 and report topline data in the fourth quarter of 2024.
  • In December 2023, Fractyl presented preclinical findings in an oral presentation at the World Congress of Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting.
  • Cash Position: As of December 31, 2023, Fractyl had approximately $33.2 million in cash and cash equivalents.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Lundi, avril 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

PanTher Therapeutics Presents Positive First-in-Human Data for PTM-101 in Pancreatic Cancer at AACR Annual Meeting

Retrieved on: 
Lundi, avril 8, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, Toxicity, Infection, Associate, Patient, Cancer, Doctor of Philosophy, MD, Panther, AACR, Pancreatic cancer, Neoplasm, Clinical trial, Therapy, Paclitaxel, Pancreas, Pancreatitis, Safety, Monash University, Prognosis, Pharmaceutical industry

PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.

Key Points: 
  • PTM-101 was placed directly onto the pancreas, overlying the location of the tumor using standard laparoscopic equipment as part of a disease staging assessment.
  • Once in place over the tumor site, PTM-101 locally delivered a sustained dose of the chemotherapeutic agent over four weeks.
  • Approximately three weeks after placement of PTM-101, all participants began standard of care therapy, which included treatment with mFOLFIRINOX.
  • Results of the clinical trial demonstrated that PTM-101 reduced the size of pancreatic tumors in all three patients.